|
Apr 24
|
NeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year
|
|
Apr 19
|
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
|
|
Jan 9
|
Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now
|
|
Dec 12
|
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
|
|
Dec 5
|
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
|
Apr 28
|
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
|